Humanized anti-ccr2 antibodies and methods of use therefor
CA 2399080 C · Owner: Medical Research Council Technology · Inventors: O'Keefe, Theresa; O'Brien, Siobhan; Jones, S. Tarran
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g. human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof and to use , of the antibodies and fragments in therapeutic prophylactic and diagnostic , methods.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 2, 2001 and granted May 21, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 2, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 2, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.